89 related articles for article (PubMed ID: 9872489)
1. Patient noncompliance with hormone replacement therapy: a nationwide estimate using a large prescription claims database.
Faulkner DL; Young C; Hutchins D; McCollam JS
Menopause; 1998; 5(4):226-9. PubMed ID: 9872489
[TBL] [Abstract][Full Text] [Related]
2. Changes in pattern of use, clinical characteristics and persistence rate of hormone replacement therapy among postmenopausal women after the WHI publication.
Guay MP; Dragomir A; Pilon D; Moride Y; Perreault S
Pharmacoepidemiol Drug Saf; 2007 Jan; 16(1):17-27. PubMed ID: 16794994
[TBL] [Abstract][Full Text] [Related]
3. Persistence with oral and transdermal hormone replacement therapy and hospitalisation for cardiovascular outcomes.
Corrao G; Zambon A; Nicotra F; Fornari C; La Vecchia C; Mezzanzanica M; Nappi RE; Merlino L; Cesana G
Maturitas; 2007 Jul; 57(3):315-24. PubMed ID: 17485182
[TBL] [Abstract][Full Text] [Related]
4. Trends and determinants of antiresorptive drug use for osteoporosis among elderly women.
Perreault S; Dragomir A; Desgagné A; Blais L; Rossignol M; Blouin J; Moride Y; Ste-Marie LG; Fernandès JC
Pharmacoepidemiol Drug Saf; 2005 Oct; 14(10):685-95. PubMed ID: 15645517
[TBL] [Abstract][Full Text] [Related]
5. Use of HRT and the subsequent risk of cancer.
Beral V; Banks E; Reeves G; Appleby P
J Epidemiol Biostat; 1999; 4(3):191-210; discussion 210-5. PubMed ID: 10695959
[TBL] [Abstract][Full Text] [Related]
6. Compliance with drug therapies for the treatment and prevention of osteoporosis.
McCombs JS; Thiebaud P; McLaughlin-Miley C; Shi J
Maturitas; 2004 Jul; 48(3):271-87. PubMed ID: 15207894
[TBL] [Abstract][Full Text] [Related]
7. Hormone replacement therapy and cancer.
Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
[TBL] [Abstract][Full Text] [Related]
8. The effect of hormone replacement therapy on arterial blood pressure and vascular compliance in postmenopausal women with arterial hypertension.
Kawecka-Jaszcz K; Czarnecka D; Olszanecka A; Rajzer M; Jankowski P
J Hum Hypertens; 2002 Jul; 16(7):509-16. PubMed ID: 12080436
[TBL] [Abstract][Full Text] [Related]
9. Life prevalence and determinants of hormone replacement therapy in women living in Porto, Portugal.
Lucas R; Barros H
Maturitas; 2007 Jul; 57(3):226-32. PubMed ID: 17293067
[TBL] [Abstract][Full Text] [Related]
10. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.
Genazzani AR; Gadducci A; Gambacciani M
Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941
[TBL] [Abstract][Full Text] [Related]
11. Continuation of postmenopausal hormone replacement therapy in a large health maintenance organization: transdermal matrix patch versus oral estrogen therapy.
Ettinger B; Pressman A
Am J Manag Care; 1999 Jun; 5(6):779-85. PubMed ID: 10538456
[TBL] [Abstract][Full Text] [Related]
12. Noncompliance with congestive heart failure therapy in the elderly.
Monane M; Bohn RL; Gurwitz JH; Glynn RJ; Avorn J
Arch Intern Med; 1994 Feb; 154(4):433-7. PubMed ID: 8117176
[TBL] [Abstract][Full Text] [Related]
13. Population-based hepatitis C surveillance and treatment in a national managed care organization.
Shatin D; Schech SD; Patel K; McHutchison JG
Am J Manag Care; 2004 Apr; 10(4):250-6. PubMed ID: 15124501
[TBL] [Abstract][Full Text] [Related]
14. Hormone replacement therapy in postmenopausal women: utilization of health care resources by new users.
Thorp JM; Gavin NI; Ohsfeldt RL
Am J Obstet Gynecol; 2001 Aug; 185(2):318-26. PubMed ID: 11518885
[TBL] [Abstract][Full Text] [Related]
15. Relationship of compliance with hormone replacement therapy to short-term healthcare utilization in a managed care population.
Hurley JS; Frost EJ; Trinkaus KM; Buatti MC; Emmett KE
Am J Manag Care; 1998 Dec; 4(12):1691-8. PubMed ID: 10339101
[TBL] [Abstract][Full Text] [Related]
16. Life prevalence of hormone replacement therapy and profile of users have not changed among women with self-reported menopause in the last two decades in Porto, Portugal.
Lucas R; Barros H
Climacteric; 2008 Feb; 11(1):26-31. PubMed ID: 18202962
[TBL] [Abstract][Full Text] [Related]
17. The long-term impact of 2-3 years of hormone replacement therapy on cardiovascular mortality and atherosclerosis in healthy women.
Alexandersen P; Tankó LB; Bagger YZ; Qin G; Christiansen C
Climacteric; 2006 Apr; 9(2):108-18. PubMed ID: 16698657
[TBL] [Abstract][Full Text] [Related]
18. Long-term impact of the women's health initiative on HRT.
Parente L; Uyehara C; Larsen W; Whitcomb B; Farley J
Arch Gynecol Obstet; 2008 Mar; 277(3):219-24. PubMed ID: 17713777
[TBL] [Abstract][Full Text] [Related]
19. Hormone replacement therapy and risk for coronary heart disease. Data from the CORA-study--a case-control study on women with incident coronary heart disease.
Windler E; Zyriax BC; Eidenmüller B; Boeing H
Maturitas; 2007 Jul; 57(3):239-46. PubMed ID: 17292571
[TBL] [Abstract][Full Text] [Related]
20. Physician counseling on hormone replacement therapy and bone loss: do socioeconomic and racial characteristics of women influence counseling?
Neuner JM; McCarthy EP; Davis RB; Phillips RS
J Womens Health (Larchmt); 2003 Jun; 12(5):495-504. PubMed ID: 12869297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
